Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature

References

• Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy N, NIH Consensus Development Panel on Osteoporosis Prevention D and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285(6):785–795. doi: 10.1001/jama.285.6.785
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi: 10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• SCOPE 2021: a new scorecard for osteoporosis in Europe - PMC. [cited 6 Jun 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172408/
   Google Scholar
• Nazrun AS, Tzar MN, Mokhtar SA, et al. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag. 2014;10:937–948. doi: 10.2147/TCRM.S72456
   PubMed Web of Science ®Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. Patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929–1937. doi: 10.1002/jbmr.2202
   PubMed Web of Science ®Google Scholar
• Barton DW, Behrend CJ, Carmouche JJ. Rates of osteoporosis screening and treatment following vertebral fracture. Spine J. 2019;19(3):411–417. doi: 10.1016/j.spinee.2018.08.004
   PubMed Web of Science ®Google Scholar
• Ayub N, Faraj M, Ghatan S, et al. The treatment gap in osteoporosis. J Clin Med. 2021;10(13):3002. doi: 10.3390/jcm10133002
   PubMed Web of Science ®Google Scholar
• Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8(1–2):136. doi: 10.1007/s11657-013-0136-1
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031. doi: 10.1007/s00198-006-0322-8
   PubMed Web of Science ®Google Scholar
• Fardellone P, Lello S, Cano A, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther. 2019;41(8):1576–1588. doi: 10.1016/j.clinthera.2019.05.001
   PubMed Web of Science ®Google Scholar
• Cheng L-I, Durden E, Limone B, et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm. 2015;21(9):824–833. doi: 10.18553/jmcp.2015.21.9.824
   PubMed Web of Science ®Google Scholar
• Osteoporosis treatment: recent developments and ongoing challenges - ScienceDirect. [cited 26 Jun 2023]. Available from: https://www.sciencedirect.com/science/article/pii/S2213858717301882?via%3Dihub
   Google Scholar
• Cairoli E, Eller-Vainicher C, Ulivieri FM, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int. 2014;25(4):1401–1410. doi: 10.1007/s00198-014-2619-3
   PubMed Web of Science ®Google Scholar
• Díez-Pérez A, Adachi JD, Adami S, et al. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29(1):260–267. doi: 10.1002/jbmr.2023
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. doi: 10.1056/NEJMoa1708322
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12. doi: 10.1007/s00198-019-05176-3
   PubMed Web of Science ®Google Scholar
• Brown JP, Engelke K, Keaveny TM, et al. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial. J Bone Miner Res. 2021;36(11):2139–2152. doi: 10.1002/jbmr.4409
   PubMed Web of Science ®Google Scholar
• Laura I, Felicia B, Alexia C, et al. Which treatment to prevent an imminent fracture? Bone Rep. 2021;15:101105. doi: 10.1016/j.bonr.2021.101105
   PubMedGoogle Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. doi: 10.1007/s00198-018-4704-5
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523. doi: 10.1016/S2213-8587(17)30138-9
   PubMed Web of Science ®Google Scholar
• Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone. 2020;139:115516. doi: 10.1016/j.bone.2020.115516
   PubMed Web of Science ®Google Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2017;28(7):2023–2034. doi: 10.1007/s00198-017-4009-0
   PubMed Web of Science ®Google Scholar
• Chandran M, Mitchell PJ, Amphansap T, et al. Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. Osteoporos Int. 2021;32(7):1249–1275. doi: 10.1007/s00198-020-05742-0
   PubMed Web of Science ®Google Scholar
• Watts NB, Camacho PM, Lewiecki EM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2021;27(4):379–380. doi: 10.1016/j.eprac.2021.02.001
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26:1–46. doi: 10.4158/GL-2020-0524SUPPL
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6:212–224. doi: 10.1093/humupd/6.3.212
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA. 1999;282:637–645. doi: 10.1001/jama.282.7.637
   PubMed Web of Science ®Google Scholar
• Christiansen C, Chesnut CH, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010;11(1):130. doi: 10.1186/1471-2474-11-130
   PubMedGoogle Scholar
• Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005;328(3):688–696. doi: 10.1016/j.bbrc.2004.11.097
   PubMed Web of Science ®Google Scholar
• Sex steroids and the construction and conservation of the adult skeleton | endocrine reviews | Oxford Academic. [cited 3 Aug 2023]. Available from: https://academic.oup.com/edrv/article/23/3/279/2424167?login=true
   Google Scholar
• Jobke B, Milovanovic P, Amling M, et al. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone. 2014;59:37–43. doi: 10.1016/j.bone.2013.10.024
   PubMed Web of Science ®Google Scholar
• Hayes KN, Winter EM, Cadarette SM, et al. Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med. 2021;10(5):1140. doi: 10.3390/jcm10051140
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249. doi: 10.1359/JBMR.040325
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal OsteoporosisA Randomized controlled trial. JAMA. 1999;282:1344–1352. doi: 10.1001/jama.282.14.1344
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11(1):83–91. doi: 10.1007/s001980050010
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. doi: 10.1056/NEJMoa067312
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535–1541. doi: 10.1016/S0140-6736(96)07088-2
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (Murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–195. doi: 10.1359/jbmr.081112
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2015;26(10):2521–2527. doi: 10.1007/s00198-015-3174-2
   PubMed Web of Science ®Google Scholar
• Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women Previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291. doi: 10.1097/AOG.0b013e318291718c
   PubMed Web of Science ®Google Scholar
• Lin T, Wang C, Cai X-Z, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012;66(4):399–408. doi: 10.1111/j.1742-1241.2011.02806.x
   PubMed Web of Science ®Google Scholar
• Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48–54. doi: 10.1016/j.bone.2013.10.006
   PubMed Web of Science ®Google Scholar
• Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81. doi: 10.1359/jbmr.090716
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Makras P. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179(1):R31–R45. doi: 10.1530/EJE-18-0056
   PubMed Web of Science ®Google Scholar
• Lindsay R, Krege JH, Marin F, et al. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016;27(8):2395–2410. doi: 10.1007/s00198-016-3534-6
   PubMed Web of Science ®Google Scholar
• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use | endocrine reviews | Oxford Academic. [cited 2 Jun 2023]. Available from: https://academic.oup.com/edrv/article/26/5/688/2355192?login=true
   Google Scholar
• Brent MB. Abaloparatide: A review of preclinical and clinical studies. Eur J Pharmacol. 2021;909:174409. doi: 10.1016/j.ejphar.2021.174409
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1‒34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi: 10.1056/NEJM200105103441904
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733. doi: 10.1001/jama.2016.11136
   PubMed Web of Science ®Google Scholar
• EMA (2022) Eladynos. In: Eur. Med. Agency. [cited 24 Jul 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos
   Google Scholar
• Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther. 2017;11:1221–1231. doi: 10.2147/DDDT.S127568
   PubMed Web of Science ®Google Scholar
• Lim SY. Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk. Womens Health (Lond Engl). 2022;18:17455057221125576. doi: 10.1177/17455057221125577
   Google Scholar
• Romosozumab treatment in postmenopausal women with osteoporosis | NEJM. [cited 26 Jun 2023]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1607948?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
   Google Scholar
• Kanis JA, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis synopsis of a WHO report. WHO study group. Osteoporos Int. 1994 Nov;4(6):368–381. doi: 10.1007/BF01622200
   PubMed Web of Science ®Google Scholar
• Cranney A, Jamal SA, Tsang JF, et al. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007 Sep 11;177(6):575–80. doi: 10.1503/cmaj.070234
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Johansson H, et al. FRAX Update. J Clin Densitom. 2017 Jul;20(3):360–367. doi: 10.1016/j.jocd.2017.06.022
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX. Arch Osteoporos;2016. doi: 10.1007/s11657-016-0278-z
   Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi: 10.1210/jc.2019-00221
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Harvey NC, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the national osteoporosis guideline group (NOGG). Osteoporos Int. 2021 Oct;32(10):1951–1960. doi: 10.1007/s00198-021-05942-2
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281(23):2189–2197. doi: 10.1001/jama.281.23.2189
   PubMed Web of Science ®Google Scholar
• Moen MD, Keating GM. Raloxifene. Drugs. 2008;68(14):2059–2083. doi: 10.2165/00003495-200868140-00008
   PubMed Web of Science ®Google Scholar
• Cosman F. Selective estrogen-receptor modulators. Clin Geriatr Med. 2003;19:371–379. doi: 10.1016/S0749-0690(02)00114-3
   PubMed Web of Science ®Google Scholar
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year Randomized clinical trial | Geriatrics | JAMA | JAMA network. [cited 5 Jun 2023]. Available from: https://jamanetwork.com/journals/jama/fullarticle/191242
   Google Scholar
• Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf. 2002;1(1):71–78. doi: 10.1517/14740338.1.1.71
   PubMedGoogle Scholar
• Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080–1092. doi: 10.1016/S0140-6736(21)02646-5
   PubMed Web of Science ®Google Scholar
• Robinson DE, Ali MS, Pallares N, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. 2021;36(5):820–832. doi: 10.1002/jbmr.4235
   PubMed Web of Science ®Google Scholar
• Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641–648. doi: 10.1038/ki.2008.193
   PubMed Web of Science ®Google Scholar
• Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009;27(6):635–642. doi: 10.1007/s00774-009-0119-x
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Heller HJ, Odvina CV, et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2006;12:48–53. doi: 10.4158/EP.12.1.48
   Google Scholar
• Anastasilakis AD, Pepe J, Napoli N, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab. 2021;107:1441–1460. doi: 10.1210/clinem/dgab888
   Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Aghaloo T, et al. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofac Surg. 2022;80(5):920–943. doi: 10.1016/j.joms.2022.02.008
   PubMed Web of Science ®Google Scholar
• Black DM, Condra K, Adams AL, et al. Bisphosphonates and the risk of atypical femur fractures. Bone. 2022;156:116297. doi: 10.1016/j.bone.2021.116297
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Stevenson JC. Bisphosphonate drug holidays – when, why and for how long? Climacteric. 2015;18(sup2):32–38. doi: 10.3109/13697137.2015.1099092
   PubMed Web of Science ®Google Scholar
• Adler RA, Fuleihan G-H, Bauer DC, et al. Managing osteoporosis patients after long-term bisphosphonate treatment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2016;31:16–35. doi: 10.1002/jbmr.2708
   PubMed Web of Science ®Google Scholar
• Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2018;35(2):163–173. doi: 10.1007/s40266-018-0525-7
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. 2015;26(12):2773–2783. doi: 10.1007/s00198-015-3234-7
   PubMed Web of Science ®Google Scholar
• Gopaul A, Kanagalingam T, Thain J, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Arch Osteoporos. 2021;16(1):116. doi: 10.1007/s11657-021-00971-0
   PubMed Web of Science ®Google Scholar
• Clinical features of 24 patients with rebound‐associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases - Anastasilakis - 2017 - Journal of bone and mineral research - Wiley Online Library. [cited 26 Jun 2023]. Available from: https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.3110
   Google Scholar
• Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1‒34) for 2 years and relevance to human safety - John L. Vahle, Masahiko Sato, Gerald G. Long, Jamie K. Young, Paul C. Francis, Jeffery A. Engelhardt, Michael S. Westmore, Yanfei Linda Ma, James B. Nold, 2002. [cited 13 Jul 2023]. Available from: https://journals.sagepub.com/doi/10.1080/01926230252929882?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
   Google Scholar
• Gilsenan A, Midkiff K, Harris D, et al. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2021;36(2):244–251. doi: 10.1002/jbmr.4188
   PubMed Web of Science ®Google Scholar
• Subbiah V, Madsen VS, Raymond AK, et al. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010;21(6):1041–1045. doi: 10.1007/s00198-009-1004-0
   PubMed Web of Science ®Google Scholar
• Singh S, Dutta S, Khasbage S, et al. A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2022;33(1):1–12. doi: 10.1007/s00198-021-06095-y
   PubMed Web of Science ®Google Scholar
• Inose H, Kato T, Tomizawa S, et al. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: a multicenter retrospective study. Bone Rep. 2022 Nov 7;17:101635. doi: 10.1016/j.bonr.2022.101635
   PubMedGoogle Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet Lond Engl. 2017;390:1585–1594. doi: 10.1016/S0140-6736(17)31613-6
   PubMed Web of Science ®Google Scholar
• Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022;33:1243–1256. doi: 10.1007/s00198-021-06174-0
   PubMed Web of Science ®Google Scholar
• Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate - Ettinger - 2004 - Journal Of Bone And Mineral Research - Wiley Online Library. [cited 8 Aug 2023]. Available from: https://asbmr.onlinelibrary.wiley.com/doi/10.1359/JBMR.040117
   Google Scholar
• Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int. 2016;27(1):1–12. doi: 10.1007/s00198-015-3334-4
   PubMed Web of Science ®Google Scholar
• Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852–860. doi: 10.1210/jc.2007-0711
   PubMed Web of Science ®Google Scholar
• Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23(10):1591–1600. doi: 10.1359/jbmr.080506
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet Lond Engl. 2015;386:1147–1155. doi: 10.1016/S0140-6736(15)61120-5
   PubMed Web of Science ®Google Scholar
• Lamy O, Stoll D, Aubry-Rozier B, et al. Stopping Denosumab. Curr Osteoporos Rep. 2019;17(1):8–15. doi: 10.1007/s11914-019-00502-4
   PubMed Web of Science ®Google Scholar
• Zanchetta MB, Boailchuk J, Massari F, et al. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int. 2018;29(1):41–47. doi: 10.1007/s00198-017-4242-6
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17. doi: 10.1016/j.bone.2017.08.003
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Jiang LA, et al. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017;98:54–58. doi: 10.1016/j.bone.2017.03.006
   PubMed Web of Science ®Google Scholar
• Burckhardt P, Faouzi M, Buclin T, et al. Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res. 2021;36(9):1717–1728. doi: 10.1002/jbmr.4335
   PubMed Web of Science ®Google Scholar
• Kendler D, Chines A, Clark P, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2019;105:e255–e264. doi: 10.1210/clinem/dgz095
   Web of Science ®Google Scholar
• Freemantle N, Satram-Hoang S, Tang E-T, et al. Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2012;23(1):317–326. doi: 10.1007/s00198-011-1780-1
   PubMed Web of Science ®Google Scholar
• Tutaworn T, Nieves JW, Wang Z, et al. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos Int. 2023;34(3):573–584. doi: 10.1007/s00198-022-06648-9
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Langdahl BL, Marin F, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European forsteo observational study (EFOS). Osteoporos Int. 2011;22(10):2709–2719. doi: 10.1007/s00198-010-1498-5
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Ljunggren Ö, Benhamou C-L, et al. Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the extended forsteo observational study (ExFOS). Calcif Tissue Int. 2016;99(3):259–271. doi: 10.1007/s00223-016-0143-5
   PubMed Web of Science ®Google Scholar
• Kocjan T, Rajic AS, Janez A, et al. Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis. Endocr Pract. 2021;27(9):941–947. doi: 10.1016/j.eprac.2021.05.012
   PubMed Web of Science ®Google Scholar
• Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018;103:2949–2957. doi: 10.1210/jc.2018-00163
   PubMed Web of Science ®Google Scholar
• Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial - ScienceDirect. [cited 25 Jul 2023]. Available from: https://www.sciencedirect.com/science/article/pii/S0025619616306309?via%3Dihub
   Google Scholar
• Kashii M, Katamani T, Nagayama A, et al. Baseline serum P1NP level is associated with the increase in hip bone mineral density seen with romosozumab treatment in previously untreated women with osteoporosis Osteoporos Int. Osteoporosis Int. 2023 Mar;34(3):563–572. Epub 2022 Dec 31. PMID: 36585509. doi: 10.1007/s00198-022-06642-1
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34:419–428. doi: 10.1002/jbmr.3622
   PubMed Web of Science ®Google Scholar
• McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–1406. doi: 10.1002/jbmr.3452
   PubMed Web of Science ®Google Scholar
• McClung MR, Bolognese MA, Brown JP, et al. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int. 2020;31(11):2231–2241. doi: 10.1007/s00198-020-05502-0
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bone HG, Massari F, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. pag. 2019;30(12):2437–2448. doi: 10.1007/s00198-019-05146-9
   Google Scholar